Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Next Previous
Trial Profile

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 29 Aug 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
  • 22 May 2024 Results from the study demonstrating that baseline CT mucus-score predicts early ICS/LABA/LAMA treatment response and quality-of-life improvements in moderate asthma presented at the 120th International Conference of the American Thoracic Society.
  • 22 May 2024 Primary endpoint (Change from baseline airway function measured using 129-Xenon MRI ventilation defect percent at the end of 6 weeks of treatment with FF/UMEC/VI 200/62.5/25ug once daily) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top